AbCellera Reports Q2 Results with $84M in New Upfront Payments, Extends Cash Runway to 36+ Months
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera Biologics announced Q2 2026 results, securing $84 million in new upfront payments from Jazz and Vertex collaborations, which significantly improved cash flow and extended its cash runway to over 36 months.
Key Events · M&A and Partnerships · ABCL
-
New Collaboration Upfront Payments
Received $56 million upfront from Jazz Pharmaceuticals in Q2 2026 and $28 million from Vertex Pharmaceuticals in July 2026, totaling $84 million in non-dilutive funding.
-
Improved Cash Flow from Operations
Net cash used in operating activities significantly decreased to $7.6 million for the six months ended June 30, 2026, compared to $44.0 million in the prior year period, driven by upfront payments and a $36 million litigation settlement.
-
Extended Cash Runway
The company now expects its existing liquidity (cash, cash equivalents, marketable securities, and government contributions) to fund operations for at least the next 36 months.
-
Clinical Pipeline Progress
ABCL635 Phase 2 enrollment is complete with top-line data expected in August 2026, and ABCL575 Phase 1 data is expected in Q4 2026. Two other candidates, ABCL688 and ABCL386, are advancing to IND/CTA-enabling studies.
Analysis · ABCL · Life Sciences
AbCellera Biologics reported its Q2 2026 financial results, highlighting significant non-dilutive funding from new collaborations. The company received $56 million upfront from Jazz Pharmaceuticals in Q2 and an additional $28 million from Vertex Pharmaceuticals in July 2026, totaling $84 million in new upfront payments. This, combined with the full collection of a $36 million litigation settlement, significantly improved cash flow from operations, reducing cash used from $44.0 million in H1 2025 to $7.6 million in H1 2026. The company now projects its liquidity to be sufficient for at least the next 36 months. While total revenue decreased year-over-year, the strategic shift towards internal pipeline development and successful non-dilutive funding are key positives for a clinical-stage biotech.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABCL was trading at $5.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.75 to $8.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.